Immune Response News and Research

RSS

Affiris GmbH granted a Europe-wide patent for key elements of its Alzheimer's vaccine

As a result, the company has exclusive rights of use to the peptide sequences for an innovative approach to vaccine development. The tolerability of the first Affiris vaccine, AFFITOPE AD01, is currently being tested as part of a phase I clinical trial. The lead investor in the company, MIG-Fonds, is extremely satisfied with the expanding patent portfolio of Affiris GmbH.

21 Nov 2007

Hormone norepinephrine may hasten the progression of certain blood cancers

Researchers here have shown that in cell cultures, the stress hormone norepinephrine appears to promote the biochemical signals that stimulate certain tumor cells to grow and spread.

20 Nov 2007

First chemical evidence of a sperm recognition system in the oviducts of pigs

Adding another layer of competition to the mating game, scientists are reporting possible biochemical proof that the reproductive system of female mammals can "sense" the presence of sperm and react to it by changing the uterine environment.

19 Nov 2007

HIV-1 vaccines may not be as reliable against superinfection as once thought

Natural HIV-1 infection does not always elicit a protective immune response, according to a new study published November 16 in PLoS Pathogens.

19 Nov 2007

Some viral-vector vaccines may cause more harm than good

Leading efforts to create an HIV vaccine have hinged on the use of viruses as carriers for selected elements of the HIV virus. Recently, however, evidence has emerged that some of these so-called viral vector systems may undermine the immune system and should not be used for vaccine development.

16 Nov 2007

Earlier bites by uninfected mosquitoes boost West Nile deaths in lab mice

There's one more reason to try to avoid being bitten by mosquitoes, scientists have discovered: bites from mosquitoes that aren't infected by the West Nile virus may make the disease worse in people who acquire it later from West Nile-infected mosquitoes.

16 Nov 2007

CD200 stifles anti-tumor immunity

The prognosis for individuals with metastatic melanoma (MM) is not good. Therapeutic strategies to enhance the immune response have some clinical benefit; however, most patients eventually succumb to progressive disease, in part because their immune cells known as dendritic cells (DCs) fail to sustain an effective antitumor T cell immune response.

16 Nov 2007

Tumour cells could be used to develop personalised light-activated cancer vaccines

Cancer tissue taken directly from patients could be used to produce a light-triggered vaccine to target and treat their own tumours, according to a study published in the British Journal of Cancer.

14 Nov 2007

La Jolla Institute for Allergy & Immunology to perform study on allergy molecular causes

A major study that will provide a new window into understanding and potentially treating allergies will be conducted by the La Jolla Institute for Allergy & Immunology (LIAI) under a $5 million federal contract.

14 Nov 2007

Volunteers in AIDS vaccine trial may be at greater risk of infection

Following the aborting of two international trials of an experimental AIDS vaccine, thousands of volunteers have been told the vaccine may have actually raised their risk of infection.

14 Nov 2007

Anti-inflammation molecule helps fight MS-like disease

An immune system messenger molecule that normally helps quiet inflammation could be an effective tool against multiple sclerosis (MS). Neurology researchers led by Abdolmohamad Rostami, M.D., Ph.D., professor and chair of the Department of Neurology at Jefferson Medical College of Thomas Jefferson University and the Jefferson Hospital for Neuroscience in Philadelphia, have found that the protein interkeukin-27 (IL-27) helped block the onset or reverse symptoms in animals with an MS-like disease.

13 Nov 2007

Antivirals reduce deaths from flu in hospitalized patients

Adults with influenza infections serious enough to require hospitalization are much less likely to die from the disease if they are given antiviral medications, according to a new study published in the December 15 issue of Clinical Infectious Diseases, currently available online.

13 Nov 2007

Seattle Post-Intelligencer examines reactions of people who participated in Merck's canceled HIV vaccine

The Seattle Post-Intelligencer on Friday examined the reaction of volunteers in the Seattle arm of Merck's recently halted HIV vaccine trial. According to the Post-Intelligencer, participants who were interviewed on the condition of anonymity have voiced "decidedly mixed feelings" about participating in the trial because of safety concerns (Paulson, Seattle Post-Intelligencer, 11/9).

12 Nov 2007